Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mibavademab (REGN4461) Phase 1 Study in Healthy and Overweight/Obese Adults
NCT03530514Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mibavademab in obesity and Overweight (10 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Number of treatment-emergent adverse events. Started Apr 2018; status: completed.
02
Drugs
mibavademab
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03530514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530514.